<DOC>
	<DOCNO>NCT01499563</DOCNO>
	<brief_summary>The purpose study evaluate whether ITI-007 effective reducing symptom associate schizophrenia patient acute worsen psychosis . Patients randomly assign receive one two dose ITI-007 , placebo , positive control . The primary goal assess effect ITI-007 psychosis . The safety ITI-007 also assess .</brief_summary>
	<brief_title>Study Novel Antipsychotic ITI-007 Schizophrenia</brief_title>
	<detailed_description>The study conduct randomize , double-blind , placebo-controlled , multi-center study patient diagnose schizophrenia acute exacerbation psychosis . The efficacy safety two dose level ITI-007 administer daily 28 day evaluate compare placebo ; risperidone include positive control . Upon completion inpatient 28-day Study Treatment Period , patient start standard antipsychotic medication stabilize 5-day period discharge study clinic . Patients see final outpatient safety evaluation End-of-Study visit approximately 2 week discharge .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Patient 's age 1855 Patient current diagnosis schizophrenia experience acute exacerbation psychosis Patient history least three month exposure one antipsychotic therapy ( y ) prior response antipsychotic therapy within previous five year Any female patient pregnant breastfeed Any patient presenting concurrent dementia , delirium , mental retardation , epilepsy , druginduced psychosis , history significant brain trauma Any patient presenting schizoaffective disorder , bipolar disorder , acute mania , major depression psychotic feature Any patient consider imminent danger others Any patient hematological , renal , hepatic , endocrinological , neurological , cardiovascular disease substance abuse define protocol Any patient judge Investigator inappropriate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>